SRF Inkomsten in het verleden
Verleden criteriumcontroles 4/6
De winst van SRF is gedaald met een gemiddeld jaarlijks percentage van -2.8%, terwijl de winst van de Chemicals -industrie jaarlijks groeide met 6.1%. De inkomsten zijn groeide met een gemiddeld percentage van 7.5% per jaar. Het rendement op het eigen vermogen SRF bedraagt 13.1% en de nettomarge bedraagt 11.6%.
Belangrijke informatie
-2.82%
Groei van de winst
-2.98%
Groei van de winst per aandeel
| Chemicals Groei van de industrie | 17.68% |
| Inkomstengroei | 7.54% |
| Rendement op eigen vermogen | 13.07% |
| Nettomarge | 11.63% |
| Laatste winstupdate | 31 Mar 2026 |
Recente prestatie-updates uit het verleden
Recent updates
Narratiefupdate • Jun 06
503806: Expanded Capital Outlay Will Support Long Term Performance
Analysts have revised their price target for SRF to ₹3,579 from ₹3,841, citing updated assumptions for revenue growth, profit margins, and the discount rate, while keeping the future P/E expectation broadly similar. What's in the News SRF has scheduled a board meeting on May 5, 2026 to consider and approve the audited financial results for the quarter and year ended March 31, 2026.
Narratiefupdate • May 22
503806: Expanded Capital Outlay And Dividend Potential Will Support Future Upside
Analysts have trimmed their fair value estimate for SRF from about ₹3,155.83 to ₹2,990.35, reflecting updated assumptions around discount rate, revenue growth, profit margin and future P/E expectations. What's in the News Board meeting scheduled for May 5, 2026, to consider and approve audited financial results for the quarter and year ended March 31, 2026 (company filing).
Narratiefupdate • Apr 30
503806: Future P/E Compression Will Likely Cap Upside Despite Margin Support
The analyst price target for SRF has been adjusted from ₹2,249.74 to ₹2,200.00 as analysts factor in updated assumptions on discount rate, revenue growth, profit margin and future P/E. What's in the News SRF has scheduled a board meeting on May 05, 2026 to consider and approve the audited financial results for the quarter and year ended March 31, 2026 (company filing).Narratiefupdate • Apr 08
503806: Fair View As Higher Margins Offset Lower Future P/E Multiple
Analysts have raised their fair value estimate for SRF slightly, from ₹2,239.45 to ₹2,249.74. This reflects updated assumptions for revenue growth, profit margins, a lower assumed discount rate, and a reduced future P/E multiple.Narratiefupdate • Mar 24
503806: Elevated P E And Margins Will Likely Restrain Future Returns
Analysts have modestly increased their fair value estimate for SRF from ₹2,218.36 to ₹2,239.45, citing updated assumptions regarding revenue growth, profit margins, the discount rate, and future P/E, which together support a slightly higher price target. What's in the News SRF's board approved the appointment of Mr. Samir Kashyap as Chief Financial Officer, effective January 27, 2026.Narratiefupdate • Mar 09
503806: Elevated P E And Modest Margins Will Likely Restrain Future Returns
Analysts now set their fair value estimate for SRF at ₹2,218, compared with the previous ₹2,244. This reflects updated assumptions around discount rate, revenue growth, profit margins and future P/E expectations.Narratiefupdate • Feb 23
503806: Elevated P E And Modest Margin Outlook Will Likely Pressure Returns
Analysts have slightly raised their price target on SRF to ₹2,244, citing updated assumptions for the discount rate, revenue growth, profit margin and future P/E. These changes keep their fair value view broadly unchanged in headline terms but reflect a modestly adjusted risk and earnings profile.Narratiefupdate • Feb 09
503806: Lower Margins And Rich P E Will Likely Pressure Returns
Analysts have raised their price target on SRF to ₹2,244 from ₹2,213, citing updated assumptions on the discount rate, revenue growth, profit margins and a higher future P/E multiple. What's in the News The board has approved the appointment of Mr. Samir Kashyap as Chief Financial Officer, effective January 27, 2026.Narratiefupdate • Jan 24
503806: New Pharma Plant And CFO Appointment Will Support Future Upside
Analysts have trimmed their price target on SRF to ₹3,155.83 from ₹3,183.00, reflecting slightly more conservative assumptions on revenue growth, profit margin and future P/E, as well as a marginally higher discount rate. What's in the News Board meeting on January 20, 2026 to review unaudited financial results for the quarter and nine months ended December 31, 2025, consider a new pharma intermediate plant project, and discuss a second interim dividend for FY 2025-26 (company filing).Narratiefupdate • Jan 10
503806: Future Capacity Expansion And CFO Transition Will Support Long Term Prospects
Analysts have kept their fair value estimate for SRF steady at ₹3,841, with only small tweaks to assumptions such as the discount rate, revenue growth, profit margin and future P/E that feed into the updated target. This signals broadly consistent expectations compared with prior research.Narratiefupdate • Dec 26
503806: Future Specialty Fluoropolymer Capacity Expansion May Support Long Term Profitability
Analysts have modestly raised their price target on SRF to a new level, in line with incremental improvements in projected revenue growth, profit margins, and a slightly lower future valuation multiple, signaling a cautiously stronger outlook for the stock. What's in the News Chief Financial Officer Rahul Jain will step down from his role at the close of business on 12 December 2025, with SRF initiating the process to identify a successor and ensure a smooth transition (Key Developments).Narratiefupdate • Dec 12
503806: Lower Discount Rate May Support Stronger Long Term Profitability
Analysts have raised their fair value estimate for SRF by approximately $191 to $3,841 per share, citing a modestly lower discount rate and slightly higher long term profit margin expectations that more than offset a small reduction in projected revenue growth. What's in the News Chief Financial Officer Rahul Jain will step down from his role at the close of business on 12 December 2025.Narratiefupdate • Nov 27
503806: CFO Transition And New Facility Approval Will Drive Upside Ahead
Analysts have adjusted their price target for SRF slightly upward from $3,182.93 to $3,183.00, citing minor changes in underlying financial assumptions such as discount rate and projected margin. What's in the News Chief Financial Officer Rahul Jain will step down at the close of business on December 12, 2025.Narratiefupdate • Nov 12
503806: Upcoming CFO Departure And Facility Decision Will Shape Outlook
Analysts have raised their price target for SRF from $3,138.07 to $3,182.93, citing updated forecasts that reflect slight adjustments in growth and profitability assumptions. What's in the News SRF Limited's Chief Financial Officer, Rahul Jain, announced he will step down from his position at the close of business on December 12, 2025.Narratiefupdate • Oct 29
New Facility And Supply Chain Moves Will Drive Balanced Opportunity Ahead
Analysts have slightly raised their price target for SRF from $3,137.83 to $3,138.07, citing improved profit margin projections as well as a modest increase in anticipated revenue growth. What's in the News SRF Limited will hold a Board Meeting on October 27, 2025, to consider and approve the un-audited financial results for the quarter and half year ended September 30, 2025.Narratiefupdate • Oct 15
Sustainability And Capacity Upgrades Will Transform Specialty Chemicals
Analysts have increased their price target for SRF from $3,104.79 to $3,137.83, reflecting updated expectations for the company's financial outlook. What's in the News The Chemours Company and SRF Limited have signed strategic agreements to enhance the global supply chain for fluoropolymers and fluoroelastomers (Key Developments).Narratiefupdate • Sep 05
Sustainability And Capacity Upgrades Will Transform Specialty Chemicals
With no meaningful change in either the discount rate or forward P/E multiple, analysts have maintained SRF's fair value estimate at ₹3105. What's in the News SRF Limited has entered into strategic agreements with The Chemours Company to strengthen Chemours' global supply chain for fluoropolymers and fluoroelastomers, leveraging SRF's manufacturing capabilities.
Nieuw narratief • Nov 28
Specialty Chemicals Innovations And Global Demand Empower Revenue Growth Journey
SRF's Specialty Chemicals growth and increased production should drive revenue and improve margins due to new product launches and efficiency gains.Opbrengsten en kosten
Opbrengsten en kosten
Hoe SRF geld verdient en uitgeeft. Gebaseerd op laatst gerapporteerde winst, op LTM-basis.
Inkomsten en omzetgeschiedenis
| Datum | Inkomsten | Inkomsten | G+A Uitgaven | R&D-uitgaven |
|---|---|---|---|---|
| 31 Mar 26 | 157,865 | 18,352 | 12,109 | 0 |
| 31 Dec 25 | 154,847 | 17,792 | 11,548 | 0 |
| 30 Sep 25 | 152,635 | 16,176 | 11,347 | 0 |
| 30 Jun 25 | 150,476 | 14,309 | 11,110 | 0 |
| 31 Mar 25 | 146,931 | 12,508 | 10,859 | 0 |
| 31 Dec 24 | 139,495 | 11,469 | 10,547 | 0 |
| 30 Sep 24 | 135,112 | 11,293 | 10,378 | 0 |
| 30 Jun 24 | 132,643 | 12,286 | 10,110 | 0 |
| 31 Mar 24 | 131,385 | 13,357 | 9,768 | 0 |
| 31 Dec 23 | 133,469 | 14,760 | 9,422 | 0 |
| 30 Sep 23 | 137,635 | 17,334 | 9,086 | 0 |
| 30 Jun 23 | 143,139 | 19,136 | 8,772 | 0 |
| 31 Mar 23 | 148,703 | 21,623 | 8,535 | 0 |
| 31 Dec 22 | 146,416 | 22,055 | 8,435 | 0 |
| 30 Sep 22 | 145,178 | 22,002 | 8,401 | 0 |
| 30 Jun 22 | 136,290 | 21,016 | 8,226 | 0 |
| 31 Mar 22 | 124,337 | 18,889 | 8,104 | 0 |
| 31 Dec 21 | 114,919 | 16,647 | 7,597 | 0 |
| 30 Sep 21 | 102,924 | 14,834 | 7,108 | 0 |
| 30 Jun 21 | 95,543 | 14,167 | 6,659 | 0 |
| 31 Mar 21 | 84,000 | 11,983 | 6,393 | 0 |
| 31 Dec 20 | 76,502 | 10,110 | 6,079 | 0 |
| 30 Sep 20 | 73,543 | 10,322 | 5,868 | 0 |
| 30 Jun 20 | 69,913 | 9,174 | 5,652 | 0 |
| 31 Mar 20 | 72,094 | 9,159 | 5,567 | 0 |
| 31 Dec 19 | 78,817 | 9,511 | 6,060 | 0 |
| 30 Sep 19 | 78,411 | 7,592 | 5,862 | 0 |
| 30 Jun 19 | 71,216 | 6,331 | 4,993 | 0 |
| 31 Mar 19 | 70,996 | 5,916 | 4,901 | 0 |
| 31 Dec 18 | 72,329 | 5,747 | 5,306 | 0 |
| 30 Sep 18 | 66,660 | 5,402 | 5,199 | 0 |
| 30 Jun 18 | 60,370 | 4,917 | 4,777 | 0 |
| 31 Mar 18 | 55,890 | 4,617 | 5,035 | 0 |
| 31 Dec 17 | 53,026 | 4,670 | 4,951 | 0 |
| 30 Sep 17 | 50,385 | 4,442 | 4,827 | 0 |
| 30 Jun 17 | 48,952 | 4,642 | 4,465 | 0 |
| 31 Mar 17 | 48,218 | 5,150 | 4,585 | 0 |
| 31 Dec 16 | 45,833 | 4,787 | 4,491 | 0 |
| 30 Sep 16 | 45,459 | 4,709 | 4,363 | 0 |
| 30 Jun 16 | 45,980 | 4,537 | 4,016 | 0 |
| 31 Mar 16 | 45,927 | 4,299 | 4,094 | 0 |
| 31 Dec 15 | 45,353 | 3,746 | 5,788 | 0 |
| 30 Sep 15 | 45,511 | 3,453 | 5,722 | 0 |
| 30 Jun 15 | 45,759 | 3,235 | 5,701 | 0 |
Kwaliteitswinsten: 503806 heeft hoge kwaliteitsinkomsten.
Groeiende winstmarge: De huidige netto winstmarges (11.6%) 503806 } zijn hoger dan vorig jaar (8.5%).
Analyse vrije kasstroom versus winst
Analyse van de winstgroei in het verleden
Winsttrend: De winst van 503806 is de afgelopen 5 jaar met 2.8% per jaar gedaald.
Versnelling van de groei: De winstgroei van 503806 over het afgelopen jaar ( 46.7% ) overtreft het 5-jarig gemiddelde ( -2.8% per jaar).
Winst versus industrie: De winstgroei 503806 over het afgelopen jaar ( 46.7% ) overtrof de Chemicals -sector 12.6%.
Rendement op eigen vermogen
Hoge ROE: Het Rendement op eigen vermogen ( 13.1% ) van 503806 wordt als laag beschouwd.
Rendement op activa
Rendement op geïnvesteerd vermogen
Ontdek sterk presterende bedrijven uit het verleden
Bedrijfsanalyse en status van financiële gegevens
| Gegevens | Laatst bijgewerkt (UTC-tijd) |
|---|---|
| Bedrijfsanalyse | 2026/06/10 20:34 |
| Aandelenkoers aan het einde van de dag | 2026/06/10 00:00 |
| Inkomsten | 2026/03/31 |
| Jaarlijkse inkomsten | 2026/03/31 |
Gegevensbronnen
De gegevens die gebruikt zijn in onze bedrijfsanalyse zijn afkomstig van S&P Global Market Intelligence LLC. De volgende gegevens worden gebruikt in ons analysemodel om dit rapport te genereren. De gegevens zijn genormaliseerd, waardoor er een vertraging kan optreden voordat de bron beschikbaar is.
| Pakket | Gegevens | Tijdframe | Voorbeeld Amerikaanse bron * |
|---|---|---|---|
| Financiële gegevens bedrijf | 10 jaar |
| |
| Consensus schattingen analisten | +3 jaar |
|
|
| Marktprijzen | 30 jaar |
| |
| Eigendom | 10 jaar |
| |
| Beheer | 10 jaar |
| |
| Belangrijkste ontwikkelingen | 10 jaar |
|
* Voorbeeld voor effecten uit de VS, voor niet-Amerikaanse effecten worden gelijkwaardige formulieren en bronnen gebruikt.
Tenzij anders vermeld zijn alle financiële gegevens gebaseerd op een jaarperiode, maar worden ze elk kwartaal bijgewerkt. Dit staat bekend als Trailing Twelve Month (TTM) of Last Twelve Month (LTM) gegevens. Meer informatie.
Analysemodel en Snowflake
Details van het analysemodel dat is gebruikt om dit rapport te genereren zijn beschikbaar op onze Github-pagina. We hebben ook handleidingen over hoe je onze rapporten kunt gebruiken en tutorials op YouTube.
Leer meer over het team van wereldklasse dat het Simply Wall St-analysemodel heeft ontworpen en gebouwd.
Industrie en sector
Onze industrie- en sectormetrics worden elke 6 uur berekend door Simply Wall St, details van ons proces zijn beschikbaar op Github.
Bronnen van analisten
SRF Limited wordt gevolgd door 42 analisten. 30 van deze analisten hebben de schattingen van de omzet of winst ingediend die zijn gebruikt als input voor ons rapport. Inzendingen van analisten worden de hele dag door bijgewerkt.
| Analist | Instelling |
|---|---|
| null null | 360 ONE Capital Market Private Limited |
| Kumar Saumya Singh | Ambit Capital |
| Nitin Bhasin | Ambit Capital |